FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204246306> ?p ?o ?g. }

• W3204246306 abstract "Glutamergic system dysfunction has been implicated in the pathophysiology of bipolar depression. This is an update of the 2015 Cochrane Review for the use of glutamate receptor modulators for depression in bipolar disorder.1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder. 2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing depressive symptoms.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase and PsycINFO all years to July 2020. We did not apply any restrictions to date, language or publication status.RCTs comparing ketamine or other glutamate receptor modulators with other active psychotropic drugs or saline placebo in adults with bipolar depression.Two review authors independently selected studies for inclusion, assessed trial quality and extracted data. Primary outcomes were response rate and adverse events. Secondary outcomes included remission rate, depression severity change scores, suicidality, cognition, quality of life, and dropout rate. The GRADE framework was used to assess the certainty of the evidence.Ten studies (647 participants) were included in this review (an additional five studies compared to the 2015 review). There were no additional studies added to the comparisons identified in the 2015 Cochrane review on ketamine, memantine and cytidine versus placebo. However, three new comparisons were found: ketamine versus midazolam, N-acetylcysteine versus placebo, and riluzole versus placebo. The glutamate receptor modulators studied were ketamine (three trials), memantine (two), cytidine (one), N-acetylcysteine (three), and riluzole (one). Eight of these studies were placebo-controlled and two-armed. In seven trials the glutamate receptor modulators had been used as add-on drugs to mood stabilisers. Only one trial compared ketamine with an active comparator, midazolam. The treatment period ranged from a single intravenous administration (all ketamine studies), to repeated administration for riluzole, memantine, cytidine, and N-acetylcysteine (with a follow-up of eight weeks, 8 to 12 weeks, 12 weeks, and 16 to 20 weeks, respectively). Six of the studies included sites in the USA, one in Taiwan, one in Denmark, one in Australia, and in one study the location was unclear. All participants had a primary diagnosis of bipolar disorder and were experiencing an acute bipolar depressive episode, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders fourth edition (IV) or fourth edition text revision (IV-TR). Among all glutamate receptor modulators included in this review, only ketamine appeared to be more efficacious than placebo 24 hours after infusion for response rate (odds ratio (OR) 11.61, 95% confidence interval (CI) 1.25 to 107.74; P = 0.03; participants = 33; studies = 2; I² = 0%, low-certainty evidence). Ketamine seemed to be more effective in reducing depression rating scale scores (MD -11.81, 95% CI -20.01 to -3.61; P = 0.005; participants = 32; studies = 2; I2 = 0%, very low-certainty evidence). There was no evidence of ketamine's efficacy in producing remission over placebo at 24 hours (OR 5.16, 95% CI 0.51 to 52.30; P = 0.72; participants = 33; studies = 2; I2 = 0%, very low-certainty evidence). Evidence on response, remission or depression rating scale scores between ketamine and midazolam was uncertain at 24 hours due to very low-certainty evidence (OR 3.20, 95% CI 0.23 to 45.19). In the one trial assessing ketamine and midazolam, there were no dropouts due to adverse effects or for any reason (very low-certainty evidence). Placebo may have been more effective than N-acetylcysteine in reducing depression rating scale scores at three months, although this was based on very low-certainty evidence (MD 1.28, 95% CI 0.24 to 2.31; participants = 58; studies = 2). Very uncertain evidence found no difference in response at three months (OR 0.82, 95% CI 0.32 to 2.14; participants = 69; studies = 2; very low-certainty evidence). No data were available for remission or acceptability. Extremely limited data were available for riluzole vs placebo, finding only very-low certainty evidence of no difference in dropout rates (OR 2.00, 95% CI 0.31 to 12.84; P = 0.46; participants = 19; studies = 1; I2 = 0%).It is difficult to draw reliable conclusions from this review due to the certainty of the evidence being low to very low, and the relatively small amount of data usable for analysis in bipolar disorder, which is considerably less than the information available for unipolar depression. Nevertheless, we found uncertain evidence in favour of a single intravenous dose of ketamine (as add-on therapy to mood stabilisers) over placebo in terms of response rate up to 24 hours, however ketamine did not show any better efficacy for remission in bipolar depression. Even though ketamine has the potential to have a rapid and transient antidepressant effect, the efficacy of a single intravenous dose may be limited. We did not find conclusive evidence on adverse events with ketamine, and there was insufficient evidence to draw meaningful conclusions for the remaining glutamate receptor modulators. However, ketamine's psychotomimetic effects (such as delusions or delirium) may have compromised study blinding in some studies, and so we cannot rule out the potential bias introduced by inadequate blinding procedures. To draw more robust conclusions, further methodologically sound RCTs (with adequate blinding) are needed to explore different modes of administration of ketamine, and to study different methods of sustaining antidepressant response, such as repeated administrations." @default.
• W3204246306 created "2021-10-11" @default.
• W3204246306 creator A5007077090 @default.
• W3204246306 creator A5016198159 @default.
• W3204246306 creator A5021170166 @default.
• W3204246306 creator A5024098703 @default.
• W3204246306 creator A5035860870 @default.
• W3204246306 creator A5040104384 @default.
• W3204246306 creator A5044652888 @default.
• W3204246306 creator A5047513610 @default.
• W3204246306 creator A5066718528 @default.
• W3204246306 creator A5067564618 @default.
• W3204246306 creator A5073942824 @default.
• W3204246306 creator A5074939684 @default.
• W3204246306 date "2021-10-08" @default.
• W3204246306 modified "2023-09-25" @default.
• W3204246306 title "Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder" @default.
• W3204246306 cites W1247968195 @default.
• W3204246306 cites W1591259115 @default.
• W3204246306 cites W1592228396 @default.
• W3204246306 cites W1746481573 @default.
• W3204246306 cites W1868235462 @default.
• W3204246306 cites W1904816587 @default.
• W3204246306 cites W1906130536 @default.
• W3204246306 cites W1924706543 @default.
• W3204246306 cites W1964162160 @default.
• W3204246306 cites W1965692095 @default.
• W3204246306 cites W1966977193 @default.
• W3204246306 cites W1976277684 @default.
• W3204246306 cites W1979534890 @default.
• W3204246306 cites W1983159214 @default.
• W3204246306 cites W1984344128 @default.
• W3204246306 cites W1990807777 @default.
• W3204246306 cites W1991536770 @default.
• W3204246306 cites W1993300625 @default.
• W3204246306 cites W1999810166 @default.
• W3204246306 cites W2001307836 @default.
• W3204246306 cites W2003490971 @default.
• W3204246306 cites W2003982930 @default.
• W3204246306 cites W2005846380 @default.
• W3204246306 cites W2016514813 @default.
• W3204246306 cites W2018100072 @default.
• W3204246306 cites W2021437265 @default.
• W3204246306 cites W2022579575 @default.
• W3204246306 cites W2024075080 @default.
• W3204246306 cites W2026977189 @default.
• W3204246306 cites W2035421865 @default.
• W3204246306 cites W2036379170 @default.
• W3204246306 cites W2037377025 @default.
• W3204246306 cites W204046373 @default.
• W3204246306 cites W2047482781 @default.
• W3204246306 cites W2049165791 @default.
• W3204246306 cites W2053845575 @default.
• W3204246306 cites W2063543227 @default.
• W3204246306 cites W2064395261 @default.
• W3204246306 cites W2074535951 @default.
• W3204246306 cites W2077771812 @default.
• W3204246306 cites W2086043739 @default.
• W3204246306 cites W2089351762 @default.
• W3204246306 cites W2092724165 @default.
• W3204246306 cites W2095493176 @default.
• W3204246306 cites W2095682198 @default.
• W3204246306 cites W2100278846 @default.
• W3204246306 cites W2106636235 @default.
• W3204246306 cites W2108403304 @default.
• W3204246306 cites W2111112809 @default.
• W3204246306 cites W2114525052 @default.
• W3204246306 cites W2114613490 @default.
• W3204246306 cites W2115934049 @default.
• W3204246306 cites W2118761224 @default.
• W3204246306 cites W2125435699 @default.
• W3204246306 cites W2128309600 @default.
• W3204246306 cites W2128886090 @default.
• W3204246306 cites W2130235475 @default.
• W3204246306 cites W2131823335 @default.
• W3204246306 cites W2132249192 @default.
• W3204246306 cites W2132517122 @default.
• W3204246306 cites W2133373104 @default.
• W3204246306 cites W2134058147 @default.
• W3204246306 cites W2135163623 @default.
• W3204246306 cites W2141217193 @default.
• W3204246306 cites W2149154629 @default.
• W3204246306 cites W2150287316 @default.
• W3204246306 cites W2153037374 @default.
• W3204246306 cites W2156098321 @default.
• W3204246306 cites W2157040702 @default.
• W3204246306 cites W2157823046 @default.
• W3204246306 cites W2161282771 @default.
• W3204246306 cites W2165414412 @default.
• W3204246306 cites W2167193785 @default.
• W3204246306 cites W2167251944 @default.
• W3204246306 cites W2170790660 @default.
• W3204246306 cites W2320144817 @default.
• W3204246306 cites W2385546112 @default.
• W3204246306 cites W2410366392 @default.
• W3204246306 cites W2416086090 @default.
• W3204246306 cites W2430482639 @default.
• W3204246306 cites W2494513054 @default.
• W3204246306 cites W2560359312 @default.
• W3204246306 cites W2567515397 @default.

• next